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Highlights 
 
 Inflammatory biotransformation dynorphin 1-17 produces peptide fragments that 
retain kappa and delta opioid receptor activity. 
 Dynorphin 1-7 a metabolite of dynorphin 1-17 is a potent kappa and delta opioid 
receptor agonist 
 Dynorphin 1-7 mediates analgesia is a model of inflammatory pain 
 Dynorphin 1-7 undergoes rapid biotransformation in an inflammatory environment 
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Abstract 
Background: Dynorphin 1-17 is an endogenous peptide that is released at sites of 
inflammation by leukocytes, binding preferentially to κ-opioid receptors (KOP) to mediate 
nociception. We have previously shown that dynorphin 1-17 is rapidly biotransformed to 
smaller peptide fragments in inflamed tissue homogenate. This study aimed to determine the 
efficacy and potency of selected dynorphin fragments produced in an inflamed environment 
at the KOP, μ and δ-opioid receptors (MOP and DOP respectively) and in a model of 
inflammatory pain.  Functional activity of Dynorphin 1-17 and fragments (1-6, 1-7 and 1-9) 
were screened over a range of concentrations against forskolin stimulated human embryonic 
kidney 293 (HEK) cells stably transfected with one of KOP, MOP or DOP. The analgesic 
activity of dynorphin 1-7 in a unilateral model of inflammatory pain was subsequently tested. 
Rats received unilateral intraplantar injections of Freund’s Complete Adjuvant to induce 
inflammation. After six days rats received either dynorphin 1-7, 1-17 or the selective KOP 
agonist U50488H and mechanical allodynia determined. Dynorphin 1-7 and 1-9 displayed the 
greatest activity across all receptor subtypes, while dynorphin 1-7, 1-9 and 1-17 displaying a 
potent activation of both KOP and DOP evidenced by cAMP inihibition.  Administration of 
dynorphin 1-7 and U50488H, but not dynorphin 1-17 resulted in a significant increase in paw 
pressure threshold at an equimolar dose suggesting the small peptide dynorphin 1-7 mediates 
analgesia. These results show that dynorphin fragments produced in an inflamed tissue 
homogenate have changed activity at the opioid receptors and that dynorphin 1-7 mediates 
analgesia. 
 
Abbreviations: Freund’s Complete Adjuvant; FCA, κ-opioid receptor; KOP, μ-opioid 
receptor; MOP, δ-opioid receptor; DOP, human embryonic kidney 293; HEK, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid; HEPES, bovine serum albumin; BSA,  
 
Keywords: dynorphin; cAMP; opioid receptors; anti-nociception; biotransformation; 
inflammation; LCMS  
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1. Introduction 
Dynorphins are a series of peptides that bind to the κ-opioid receptor (KOP) and mediate 
anti-nociception peripherally [1, 2]. In the periphery, leukocytes have been shown to invade 
sites of inflammation and release opioid peptides including dynorphin A 1-17, in response to 
pro-inflammatory interleukin-1β and lipopolysaccharide [3-5]. The opioid receptors μ-opioid 
receptor (MOP), δ-opioid receptor (DOP) and KOP mediate analgesia both peripherally and 
centrally and the release of endogenous opioids at the peripheral site of inflammation acts as 
an endogenous analgesic [6]. 
Our group has demonstrated that dynorphin A 1-17 undergoes extensive and rapid 
biotransformation in an inflamed rat paw tissue homogenate, producing a unique set of 
dynorphin fragments [7]. It is likely that a similar set of fragments is produced from 
dynorphin released from leukocytes into inflamed tissue and that these dynorphin fragments 
mediate pain and inflammation. Recently we have shown that these dynorphin fragments 
mediate inflammation through activity at opioid receptors and through other non-opioid 
mechanisms [8]. We have also shown that the endogenous ligand, β-endorphin, with the 
highest affinity for MOP, is rapidly biotransformed in inflamed tissue homogenate [9] and 
that these fragments have continued activity at the MOP, altered activity at the DOP, and no 
efficacy at the KOP [10]. It is unclear what effect the biotransformation of dynorphin has on 
the resulting fragments pharmacology at the opioid receptors. 
Opioid receptors are G protein-coupled receptors and when activated the Gi subunit 
dissociates and inhibits adenylyl cyclase, inihibiting cAMP production, correlating with the 
inhibition of nociception [11]. It has previously been reported that the removal of the N-
terminal tyrosine-1 results in the inactivation of dynorphin at the KOP, while shorter N-
terminal conserved fragments have decreased efficacy at the KOP but increased efficacy at 
both the μ-opioid receptor (MOP) and the δ-opioid receptor (DOP), in a guinea pig ileum 
assay [12, 13]. While the guinea pig ileum organ bath preparation is an effective functional 
assay to measure the pharmacology of opioid receptor modulators, we can now measure 
directly the activity of dynorphin fragments at the receptor in cells selectively overexpressing 
transfected select opioid receptors with a cAMP alphascreen assay.  
The administration of dynorphin 1-17 has been shown to reduce peripheral hyperalgesia in a 
range of animal models of pain [1, 2]. The dynorphin fragments produced in the 
biotransformation study were produced in an inflamed tissue homogenate, leaving the 
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question of the role these dynorphin fragments play in inflammatory pain unanswered. In this 
study we firstly determined the activity of dynorphin fragments identified previously [7] at 
each opioid receptor separately by measuring intracellular cAMP  production in human 
embryonic kidney 293 (HEK) cells transfected with KOP, MOP or DOP.  The 
biotransformed dynorphin fragment that displayed the greatest activity across the opioid 
receptor classes was then selected to determine the anti-nociceptive activity in a rodent model 
of unilateral peripheral inflammation. 
2. Methods 
2.1 Cell culture 
HEK 293 cells with stable transfected FLAG-KOP, FLAG-DOP and FLAG-MOP, were a 
kind gift from Prof. Maree Smith at the University of Queensland, and the cells were grown 
separately in Dulbecco's Modified Eagle Medium (PAA laboratories, Australia) 
supplemented with 10% foetal bovine serum (PAA Laboratories, Australia) and the selective 
antibiotic G418 sulfate (0.5mg.ml-1, Invitrogen) and split every 4 days. Cells were only used 
up to passage number 50. 
2.2 cAMP alphascreen assay 
Cells were grown to confluence and harvested with Versene (Gibco Life Technologies, 
Australia) and resuspended in Hanks buffered balanced salt solution with bovine serum 
albumin (0.1%, BSA, Research Organics, Australia), 3-isobutyl-1-methylxanthine (0.5mM, 
Sigma Aldrich, Australia), HEPES (5mM, Research Organics, Australia) at a pH of 7.4. For 
HEK-fKOP cells, cells were plated into 96-half area plates (Perkin Elmer, Australia) at a 
concentration of 5000 cells per well and adenylyl cyclase was stimulated with L-858141 
(Forskolin, 100μM, an adenylyl cyclase activator, Enzo Life Sciences, New York, U.S.A). 
The HEK-fMOP were plated at a concentration of 20 000 cells per well and stimulated with 
100μM L-858141. HEK-fDOP were plated at a concentration of 20 000 cells per well and 
stimulated with 50μM of L-858141 either alone or with test ligands.  
Initially, a screen of dynorphin peptides identified in a study of dynorphin biotransformation 
was performed to identify peptides with activity at each receptor [7]. A high (1μM) and low 
concentration (10nM) of each of dynorphin 1-6, 1-7, 1-9, 1-10, 1-11, 2-17, 3-14, 6-12, 7-17, 
8-17 and 1-17 (Mimotopes, Victoria, Australia), the synthetic KOP agonist U50488H  (Enzo 
Life Sciences, New York, U.S.A) and the DOP agonist SNC80 (Enzo Life Sciences, New 
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York, U.S.A) were incubated with cells stimulated with L-858141 for 30 mins. Cells were 
lysed with a lysis buffer (5mM HEPES, 0.3% Tween 20; Research Organics, Australia, 0.1% 
BSA in water at pH 7.4), and cAMP was measured with a cAMP Alphascreen kit, as per kit 
instructions (Perkin Elmer ™, Australia) and fluorescence readings read on an Enspire plate 
reader (Perkin Elmer ™, Australia). 
The shortest dynorphin fragments that displayed efficacy in the initial screen (dynorphin 1-6, 
1-7, 1-9) along with the parent compound dynorphin 1-17 and the synthetic agonist 
U50488H, were then chosen for full dose response curves in both fKOP, fDOP and fMOP 
cell types. Dynorphin fragments (0.3 pM - 10μM in a half-log progression) were then assayed 
with the cAMP Alphascreen as described previously.  
To confirm the inhibition of cAMP production was mediated by opioid receptor type, cells 
were pre-incubated with naloxone (100 μM, 30 min; Sigma Aldrich, Australia), and then 
challenged with the opioid and L-858141 (30 min). After cell lysis, intracellular cAMP was 
measured by the alphascreen assay. 
2.3 Unilateral model of peripheral inflammation 
Male Wistar rats (200-280g) were obtained from the University of Queensland institutional 
breeding colony. Studies were approved by The University of Queensland Animal Ethics 
Committee and were to the specifications of the ARRIVE guidelines. Animals were housed 
individually in a temperature-controlled room (21 ± 2.0°C) with a 12/12-hour light/dark cycle 
with access to rat chow and water ad libitum. Animals were lightly anaesthetised with 
isoflurane (0-5%) in oxygen, their right hind paw sterilised with 70% ethanol and Freunds 
Complete Adjuvant (150 μl, FCA, Sigma Aldrich, Australia) was injected into the right hind 
paw (i.pl). Inflammation was stable for between 4-6 days following administration, and on 
day 5, rats were again briefly anaesthetised and then saline, dynorphin A 1-17, dynorphin 1-7 
or U50488H was injected into the right hind paw (50μl, i.pl, 500μM for all compounds). Paw 
volume, a measure of paw oedema, was measured on both hind paws with a plethysmometer 
(Ugo Basile, Italy) prior to FCA administration, before drug or saline administration and 24 
hours after saline or drug administration.  Paw pressure threshold was measured in a blinded 
manner on both hind paws with an analgesiometer (Ugo Basile, Italy) before FCA 
administration, before drug or saline administration and 15, 30, 60, 360, and 1440 mins (24 h) 
after drug and saline administration. Animals were euthanized by CO2 asphyxiation followed 
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by cervical dislocation. Inflamed rat paws from saline treated rats were harvested from 
euthanised animals for subsequent biotransformation studies. 
 
2.4 Dynorphin 1-7 biotransformation in inflamed tissue (pH 5.5) 
Inflamed rat paw tissue was homogenised with 10 mM PBS (1g tissue: 10ml 2-(N-
morpholino)ethanesulfonic acid buffer, Sigma Aldrich, Australia), at pH 5.5, and 
subsequently centrifuged at 4ºC at 1600 RCF for 10 minutes. The resultant supernatant was 
spiked with dynorphin 1-7 (150 µM) and incubated at 37ºC.  After incubation periods ranging 
from 0 to 120 minutes, a sample (100 µL) was removed and deproteinised (enzymes 
deactivated in the same process) by adding 200 μl of acetonitrile.  Samples were then 
incubated at room temperature for 20 minutes to complete the protein precipitation and then 
centrifuged at 25ºC at 12500 RCF for 10 minutes.  The supernatant was placed in a fresh 
microcentrifuge tube and dried on a heating block at 37°C under a gentle stream of nitrogen. 
The sample was then reconstituted in 75μL of Milli-Q water for analysis by LC-MS.  
To determine whether biotransformation of the peptides occurred throughout the duration of 
cAMP assay, dynorphin 1-6, 1-7, 1-9 and 1-17 (100μM) was incubated with HEK cells (2000 
cells/μl) in Hanks buffered balanced salt solution with BSA (0.1%), 3-isobutyl-1-
methylxanthine (0.5mM) and HEPES (5mM) at a pH of 7.4. After 0 and 30 mins the samples 
(100μl) were deproteinised as described, and samples prepared for LCMS in 100μl of Milli-Q 
water for analysis by LCMS. 
 
2.5 Liquid chromatography  
An Agilent Binary HPLC system consisting of an Agilent 1100 LC pump, an Agilent 1100 
well plate auto-sampler (Agilent Technologies, Santa Clara, CA, USA) with a Jupiter 5µ (C4, 
300 Å, 150 x 2.00 mm, 5 µm) RP HPLC column (Phenomenex, Torrance, CA, USA) were 
used for separations.  The separations were carried out using a binary solvent gradient: water 
(Milli-Q) which contained 0.1% v.v-1 formic acid as solvent A and acetonitrile which 
contained 0.1% v.v-1 formic acid as solvent B.  Both solutions were filtered through a PTFE 
0.45 µm filter (Millipore Corporation, Bedford, MA).  The injection was performed after the 
column had been equilibrated with 0% B for 10 min.  After the injection, the eluent 
composition was maintained at 0% B for the first 3 min and then changed to 50% B over the 
next 30 min.  The composition was then changed to 100% B within the next 5 min and 
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maintained for 2 min to wash the column.  The mobile phase composition was then returned 
to the original, 0 % B, within the next 3 min and the column was re-equilibrated for 10 min 
prior to the next injection.  The mobile phase flow rate was 200 μL.min-1 and the volume of 
injection was 20 µL.  
2.6 Mass spectrometry 
An API 3000 tandem mass spectrometer equipped with a turbo ion spray interface and 
supported by Analyst 1.5 software (Applied Biosystems, Foster City, CA, USA) was used to 
detect the separated fragments.  Detection was carried out in total ion current (TIC) mode 
(MS1/Q1) using default voltages, with positive ion detection. 
Fragments detected in each matrix were identified based on their mass.charge-1 (m.z-1) 
values.  A molecular weight calculator (Monroe M., Washington, USA 
http://www.alchemistmatt.com/resume/mwtoverview.html) was used for molecular weight 
computations. 
2.7 Statistical analysis 
The statistical package Graphpad Prism (Graphpad Software Inc, USA) was used for all data 
analysis. The IC50 for each dynorphin fragment was compared both with other dynorphin 
fragments at a single receptor type and between receptor types for individual dynorphin 
fragment only by comparing 95% confidence intervals.  In the unilateral model of 
inflammatory pain, groups were compared by one-way ANOVA with a Bonferroni’s multiple 
comparisons post-test where statistical significance was defined as P ≤ 0.05. 
3. Results 
3.1 Dynorphin mediated cAMP inhibition in fKOP, fMOP and fDOP-HEK 293 cells. 
An initial screen of dynorphin fragments resulted in only N-terminal fragments displaying 
blockade of cAMP production at the KOP, MOP or DOP receptors (data not shown).  
Dynorphins 1-6, 1-7, 1-9 and 1-17 were selected for full dose-response curve due to their 
greater potency in the initial screen and shorter amino acid length. In HEK-fKOP cells 
dynorphin 1-7, 1-9 and 1-17 displayed similar potencies (Figure 1.a, Table 1). Dynorphin 1-6 
displayed limited activity at the KOP receptor in regard to cAMP inhibition, with some 
inhibition of cAMP production only observed at 1μM. The blockade of cAMP production by 
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the dynorphin fragments was confirmed to be opioid mediated with the non-selective opioid 
receptor antagonist, naloxone (Figure 1.b), reversing the inhibition of cAMP production.   
Concentration-response assays performed in HEK-fMOP cells demonstrated that all 
fragments displayed low potencies at the MOP. While Dynorphin 1-6 displayed significantly 
more potent activity at MOP in comparison to KOP, the fragments IC50 was in the 
micromolar range. Of all the fragments examined dynorphin 1-7 showed the greatest potency 
at MOP with a significantly more potent activation of the receptor in comparison to the 
parent peptide dynorphin 1-17, albeit at 230 nM  (Figure 2.a, Table 1.). We have previously 
published the efficacy of the selective MOP opioid fentanyl in the HEK-fMOP cells, and all 
dynorphin fragments were ≈ 50-fold less potent at MOP than fentanyl in these cells further 
demonstrating their low potency. The blockade of cAMP production by the dynorphin 
fragments was confirmed to be mediated by the MOP with the non-selective opioid receptor 
antagonist, naloxone (Figure 2.b). A significant decrease in cAMP production was seen with 
30μM of each of the dynorphin fragments 1-6, 1-7, 1-9 and 1-17, and this decrease was 
reversed when cells were incubated with naloxone (100μM) prior to peptide exposure.  
 
Concentration-response assays performed in HEK-fDOP cells resulted again in a different 
potency order in comparison to the HEK-fKOP and the HEK-fMOP cells. Dynorphin 1-9 was 
the most potent fragment, and had a significantly lower IC50 than dynorphin 1-6, dynorphin 
1-17 and the synthetic DOP agonist, SNC80 (Figure 3.a.). Dynorphin 1-7, dynorphin 1-17, 
SNC80 had similar potencies, while dynorphin 1-6 had a significantly higher IC50 (p≤0.05; 
10 fold lower potency) than all the other compounds tested (Figure 3.a.). A significant 
decrease in cAMP production was seen when using 30nM of the respective dynorphin 
fragments and SNC80 (p≤0.05), and this was inhibited by naloxone (100µM). 
 
3.2 Unilateral inflammatory model of mechanical nociception.   
Dynorphin 1-7 was the smallest peptide of Dynorphin 1-17 biotransformation that displayed 
the overall greatest efficacy and potency in fKOP and fDOP transfected cells and was 
selected for further studies in an animal model of unilateral inflammatory pain, along with the 
parent peptide, dynorphin 1-17 and the synthetic KOP agonist, U50488H. Treatment with 
dynorphin 1-7 (500µM, i.pl) resulted in a significant increase in paw pressure threshold at 15 
min (p≤0.05), but this effect was short-lived (Figure 4.a.); dynorphin 1-17 at an equimolar 
concentration did not cause a significant change to the animals’ paw pressure threshold.  
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U50488H (500µM) treatment resulted in an increased paw pressure threshold at 15 and 60 
min (p≤0.05) after administration (Figure 4.a.). No change in paw pressure threshold was 
seen in the contralateral paw in each treatment group indicating the anti-nociceptive effects of 
the compounds were peripherally mediated (Figure 4.c.).  
 
Administration of FCA (150µl) resulted in a significant increase in paw volume (≈ 2-fold) 
(p≤0.05), but none of the compounds administered significantly altered the animals paw 
volume (Figure 4.b.). This indicates that the anti-nociceptive effects of the compounds did 
not result from a reduction in paw inflammation. The paw volume of the contralateral paw 
that was not administered FCA remained unchanged throughout the procedure indicating the 
maintenance of unilateral inflammation (Figure 4.d.).  
 
3.3 Biotransformation of dynorphin 1-7 in inflamed paw tissue (pH 5.5) 
To investigate the likely duration of action and the metabolic products of dynorphin 1-7 in 
inflamed rat paw tissue, this tissue was harvested from rats treated with FCA only, and was 
subsequently homogenised and spiked with exogenous dynorphin 1-7 (final concentration 
150μM).  Samples were taken serially over time and their contents determined by LCMS 
analysis. Dynorphin 1-7 displayed a rapid degradation with no detectable levels by 15 min 
(Figure 5.a.). The main metabolic products included the N-terminal product, dynorphin 1-5 
(leu-enkephalin) (Figure 5.a.), the C-terminal fragments dynorphin 3-7 and 4-7 (Figure 5.c.) 
and the intermediate fragments dynorphin 2-5, 3-5 and 3-4 (Figure 5.b). The N-terminal 
fragments displayed both a rapid production and subsequent degradation, while C-terminal 
and intermediate fragments displayed slower production and degradation (Figure 5.). 
For experiments to determine the stability of dynorphin 1-6, 1-7, 1-9 and 1-17 in the cAMP 
protocol, peptides were incubated with HEK cells suspended in the assay buffer at the highest 
concentration of cells used (2000 cells/μl). Some degradation was seen with some of the 
peptides with the maximum seen with dynorphin 1-9 (56% remaining after 30 min).  No 
degradation was seen with dynorphin 1-6, while dynorphin 1-7 (82% remaining after 30 min) 
and dynorphin 1-17 (72% remaining after 30 min) showed slower degradation. 
 
4. Discussion and Conclusions 
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The release of dynorphin 1-17 by leukocytes in inflamed tissue plays a role in the control of 
inflammatory pain [3-5]. Our group has previously demonstrated that dynorphin 1-17 is 
rapidly degraded in inflamed tissue in situ resulting in a specific group of N-terminal, C-
terminal and intermediate fragments [7]. We have already shown that some of these 
fragments mediate inflammation [8], however it is yet to be shown whether these fragments 
mediate analgesia through actions at opioid receptors.  The present study investigated the 
activity at the opioid receptors of the major dynorphin fragments produced in an inflamed 
tissue homogenate to examine the contribution that these fragments play in controlling 
inflammatory pain upon the biotransformation of dynorphin 1-17.   
Dynorphin fragments that did not contain the N-terminal tyrosine-1 displayed no discernible 
efficacy at the KOP, DOP or MOP (data not shown), demonstrating that the previously 
described requirement for the leading polar amino acid of dynorphin 1-17 for opioid activity 
[12, 13]. For this reason only N-terminal fragments were selected for full concentration curve 
analysis at each receptor cell type in cAMP inhibition studies. 
The inhibition of intracellular cAMP accumulation in forskolin stimulated HEK-fKOP cells 
was first examined. While dynorphin 1-6 showed weak partial agonist behaviour (data not 
shown), the addition of the arginine-7 (Arg-7) (i.e. dynorphin 1-7) resulted in similar potency 
to that of the parent peptide, dynorphin 1-17. Others have also shown that Dynorphin 1-7 has 
a high binding affinity to KOP of 0.1nM [14]. This indicates that the charged Arg-7, and to a 
lesser extent, Arg-6, are key determinants of KOP activation and KOP mediated cAMP 
inhibition [12].  
Surprisingly, the potency of dynorphin 1-17 along with the fragments dynorphin 1-7 and 1-9 
was similar at the DOP as was observed at the KOP, while the shorter dynorphin 1-6 
displayed only significant activity at DOP. In GTP-gammaS binding assays, others have 
reported that Dynorphin 1-17 displayed a similar potency at activating KOP as our current 
study, however approximately 20 fold reduced activity at DOP [15]. The discrepancies in 
may be due to changed receptor expression resulting in a spare receptor effect or differences 
in the sensitivity of the assays used. In this study we did not use protease inhibitors to stop 
degradation of the peptides in the cAMP assay. Our results showed limited biotransformation 
of the peptides occurred over the 30 min period in the assay. While this biotransformation 
occurred, for no peptides did the concentration decrease by more than 45% and with one 
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peptide (dynorphin 1-6) showing no detectable degradation. This level of degradation is 
unlikely to have a significant effect on the IC50 of the peptides observed. 
We have previously reported the biotransformation of dynorphin 1-17 to a range of fragments 
including dynorphin 1-6, 1-7 and 1-9.  In our studies these fragments showed activity 
primarily and KOP and DOP. Taken together indicates that the release of dynorphin 1-17 in 
an inflamed environment would result in primarily KOP and DOP activation and little MOP 
activation. Our results indicate that, where DOP and KOP are co-expressed in a native tissue, 
the respective receptors will display similar activation of cell signals. 
To confirm the identity of the KOP, MOP and DOP in each HEK cell type, the effects of the 
selective synthetic KOP agonist U50488H were examined at the HEK-fKOP, fMOP and 
fDOP cells. U50488H displayed potent cAMP inhibition in the HEK-fKOP cells with an IC50 
of 2.67nM, but at the fMOP and fDOP cells U50488H displayed no cAMP inhibition at 1µM. 
The selective synthetic DOP agonist SNC80 displayed potent cAMP inhibition in the HEK-
fDOP cells. Our group has previously reported the efficacy of fentanyl in the HEK-fMOP 
cells, potently inhibiting cAMP accumulation with an IC50 of 5nM. In each HEK cell line 
transfected with the respective opioid receptors, naloxone blocked the cAMP inhibition by 
the dynorphin fragments and selective opioid agonists. These results confirm that the 
inhibition of cAMP production by the dynorphin fragments in HEK-fKOP, HEK-fMOP and 
fDOP cells was due to the inhibition of the respective transfected receptors. 
Dynorphin fragments showed approximately 100 fold lower activity at the MOP, with 
dynorphin 1-7 displaying the greatest interaction with the receptor with an IC50 of 230nM. 
This indicates that N-terminal dynorphins would only likely activate MOP if released in 
significant quantities and/or proximal to MOP receptors. In a recent study we found that β-
endorphin displayed an approximately 10 fold more efficacious response than dynorphin 1-17 
and 1-7 [10].  In an inflamed environment only low levels of dynorphins are released, while 
higher concentrations of β-endorphin have been measured [3, 16]. The low concentration of 
dynorphin released may be explained by the nanomolar potency of dynorphin and dynorphin 
fragments at the KOP receptor. 
To examine the in vivo activity of dynorphin fragments, dynorphin 1-7 was chosen due to its 
potency at KOP and DOP opioid receptors in cAMP assays and the peptides relatively low 
molecular weight. The activity of dynorphin 1-7 was examined in a model of unilateral 
inflammation, and was compared to that of the parent peptide dynorphin 1-17 and the 
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synthetic KOP agonist, U50488H. Administration of dynorphin 1-7 resulted in transient (15 
min) analgesia in comparison to the saline control while administration of U50488H resulted 
in a more prolonged analgesia (60 min). Dynorphin 1-17, when injected at an equimolar dose, 
did not result in a significant increase in paw withdrawal threshold, indicating either faster 
metabolism of the peptide, or lower activity at the receptor than dynorphin 1-7. Together, the 
data presented here and from Morgan et al. (2012) demonstrates that the release of dynorphin 
1-17 to an inflamed area likely results in the biotransformation of the peptide to active 
metabolites [7]. These metabolite display different activity at the opioid receptors compared 
to the parent dynorphin 1-17 and that the analgesia observed resulting from dynorphin 1-17 
release may be the result of a range of the dynorphin fragments and some with very limited 
efficacy. 
Dynorphin 1-7 resulted in a transient increase in the nociception threshold in the model of 
unilateral analgesia and this is likely due to a rapid metabolism of dynorphin 1-7 in the 
inflamed paw tissue.  It has previously been demonstrated that inhibition of leukocytic and 
neuronal peptidases in the inflamed paws of rats results in analgesia [17]. However, when the 
peptidase inhibitors were applied in combination with antibodies against met-enkephalin, 
leucine-enkephalin and dynorphin 1-17 to the rats paws peripherally, the analgesia was 
abolished [17].  
To further examine the effect of the inflammatory environment on dynorphin 1-7, dynorphin 
1-7 was incubated in the inflamed paw tissue at pH 5.5 in situ, modelling the inflamed acidic 
environment. Dynorphin 1-7 was biotransformed rapidly with only low levels of the parent 
peptide observed at 15 min. This rapid metabolism in situ would indicate that a similarly 
rapid metabolism would occur in in vivo, accounting for the short duration of analgesia seen 
when dynorphin 1-7 was administered into the inflamed paw (Figure 4.a). In contrast the 
synthetic KOP agonist U50488H would be more resistant to local degradation by proteases, 
allowing for the more prolonged analgesia, which was observed (Figure 4.a). On top of this 
the anti-nociceptive effects of U50488H have recently been shown to not fully be explained 
by opioid receptor activity [18]. 
The primary N-terminal metabolites of dynorphin 1-7 in the inflamed paw were dynorphin 1-
5 together with the production of dynorphin 1-6. Dynorphin 1-6 was shown to have no 
efficacy at KOP, but maintained some efficacy at MOP and DOP. It is possible that some of 
the analgesic effects of dynorphin 1-7 were due to the production of dynorphin 1-6. The 
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efficacy of dynorphin 1-5 (leu-enkephalin) at the opioid receptors was not examined in this 
study, however others have shown dynorphin 1-5 displays affinity at a DOP and MOP, but 
low affinity at KOP [12, 19] indicating that the analgesia observed may have also been 
mediated by this metabolic product. While a range of C-terminal and intermediate fragments 
were produced, the removal of the N-teminal tyrosine renders the resultant peptide fragments 
inactive at the opioid receptors as shown by the studies reported here, and by others [12].  
Cleaved dynorphin peptides have previously been shown to be promiscuous and have anti-
nociceptive activity at bradykinin and NMDA receptors [20-22]. It is possible that some of 
the biotransformation products of dynorphin 1-7 mediated analgesia in the animal model 
through these or other non-opioid mechanisms. 
In summary, this study has demonstrated the altered activity of dynorphin 1-17 metabolites 
found in inflamed tissue at the various opioid receptors.  We identified the short peptide 
dynorphin 1-7 as a metabolite with equavalent activity at DOP and KOP opioid receptors and 
the fragment resulted in significant, albeit transient analgesia when administered into an 
inflamed rat paw.   
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Figure Legends 
Figure 1. The efficacy of dynorphin fragments at the KOP. a) HEK-fKOP cells were 
treated with an adenylyl cyclase activator and increasing concentrations of dynorphin 
fragments or the KOP agonist U50488H and intracellular cAMP levels determined.   b) 
Inhibition of KOP mediated cAMP reduction by non-specific opioid antagonist naloxone 
(100μM). Data represents mean ± S.E.M, (P ≤0.05) 
 
Figure 2 The efficacy of dynorphin fragments at the MOP. a) HEK-fMOP cells were 
treated with an adenylyl cyclase activator and increasing concentrations of dynorphin 
fragments or the KOP agonist U50488H and intracellular cAMP levels determined.   b) 
Inhibition of MOP mediated cAMP reduction by the non-specific opioid antagonist naloxone 
(100μM).  Data represents mean ± S.E.M, (P ≤0.05) of 3 individual trials performed in 
triplicate for each trial. 
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Figure 3. The efficacy of dynorphin fragments at the DOP. a) HEK-fDOP cells were 
treated with an adenylyl cyclase activator and increasing concentrations of dynorphin 
fragments, the KOP agonist U50488 or the DOP agonist SNC80 and intracellular cAMP 
levels determined.  b) Inhibition of DOP mediated cAMP reduction by non-specific opioid 
antagonist naloxone (100μM). Data represents mean ± S.E.M, (P ≤0.05) of 3 individual trials 
performed in triplicate for each trial. 
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Figure 4. The efficacy of dynorphin 1-7 in a model of unilateral inflammation in the rat. 
Administration of dynorphin 1-7 and U50488H, but not dynorphin 1-17 (50 μl; 500μM) to  
an inflamed paw resulted in a significant reduction in the a) paw pressure threshold.  But no 
significant change to b) paw volume was observed with treatment of any of the ligands. No 
change in c) paw pressure threshold was observed with the contralateral non-inflamed paw, 
or d) paw volume. Data represent mean ± S.E.M, (P ≤0.05), n=5-6/ treatment group.  
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Figure 5. The production and metabolism of dynorphin 1-7 and dynorphin 1-7 
fragments in inflamed rat paw tissue, pH 5.5. The biotransformation of dynorphin 1-7 
(150μM) in homogenised inflamed rat paw tissue at pH 5.5 was determined by LCMS 
analysis and the production and metabolism plotted for a) N-terminal fragments, b) 
intermediate fragments and c) C-terminal fragments. 
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Tables 
Table 1. IC50 values for dynorphin fragments in HEK-fKOP, fMOP and fDOP 
transfected cells stimulated with forskolin. 
Ligand HEK-fKOP HEK-fMOP HEK-fDOP 
Dynorphin 1-6 No activity*  1.17µM 
(0.64-2.12 µM) 
11.02 nM*# 
(5.33 - 22.82 nM) 
Dynorphin 1-7 2.58nM 
(1.64-4.08nM) 
0.23 µM *# 
(0.13-0.3 µM) 
1.56 nM  
(1.11-2.23 nM) 
Dynorphin 1-9 2.05nM 
(1.19-3.57nM) 
0.34 µM # 
(0.12-1.06 µM) 
1.04 nM * 
(0.74-1.47 nM) 
Dynorphin 1-17 1.05 nM 
(0.57-1.93nM) 
0.6 µM # 
(0.35-1.00 µM) 
3.06 nM 
(1.87- 5.02 nM) 
U50488H 2.77nM 
(1.85-4.17nM) 
No activity No activity 
SNC80 N/A N/A 2.84 nM 
(1.89-4.27 nM) 
Fentanyl N/A 5nM (2.3-11nM) 
(Asvadi et al, 2014) 
N/A 
Data represents mean (95% confidence interval), where a significantly different IC50 (P≤0.05) 
of each dynorphin fragment in comparison to the dynorphin 1-17 in the same cell line is 
denoted by * and where a significantly different IC50 (P≤0.05) for each receptor subtype in 
comparison to KOP is denoted by #.  
 
